Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Sonja Bendig, Wencke Walter, Manja Meggendorfer, Constance Bär, Irene Fuhrmann, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach & Anna Stengel. (2021) Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma. Leukemia & Lymphoma 62:14, pages 3420-3429.
Read now
Read now
Foteini Theodorakakou, Meletios A. Dimopoulos & Efstathios Kastritis. (2021) Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development 6:3, pages 189-201.
Read now
Read now
Elisabet E. Manasanch. (2016) Myc is also the bad guy in myeloma. Leukemia & Lymphoma 57:11, pages 2485-2486.
Read now
Read now
Maria G Cortiguera, Ana Batlle-López, Marta Albajar, M Dolores Delgado & Javier León. (2015) MYC as therapeutic target in leukemia and lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 5, pages 75-91.
Read now
Read now
Efstathios Kastritis & Meletios A. Dimopoulos. (2015) Appraising myc involvement in high risk myeloma. Leukemia & Lymphoma 56:3, pages 551-552.
Read now
Read now
Articles from other publishers (28)
Aaishwarya Dhabe, Samipa Das & Mayur Parihar. (2023) Role of Conventional Cytogenetics and FISH in the Laboratory Work Up of Plasma Cell Dyscrasias. Indian Journal of Medical and Paediatric Oncology 44:05, pages 505-514.
Crossref
Crossref
Reza Nejati, Catalina Amador, Magdalena Czader, Elizabeth Thacker, Devang Thakkar, Sandeep S Dave, Ahmet Dogan, Amy Duffield, John R Goodlad, German Ott, Mariusz A Wasik, Wenbin Xiao & James R Cook. (2023) Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop. American Journal of Clinical Pathology 159:6, pages 598-613.
Crossref
Crossref
Jiehao Zhou & Mehdi Nassiri. (2022) Lymphoproliferative Neoplasms With Plasmablastic Morphology. Archives of Pathology & Laboratory Medicine 146:4, pages 407-414.
Crossref
Crossref
Nadine H. Abdallah, Moritz Binder, S. Vincent Rajkumar, Patricia T. Greipp, Prashant Kapoor, Angela Dispenzieri, Morie A. Gertz, Linda B. Baughn, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Ronald S. Go, Yi L. Hwa, Amie L. Fonder, Miriam A. Hobbs, Yi Lin, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Mustaqeem A. Siddiqui, Robert A. Kyle, P. Leif Bergsagel, Rafael Fonseca, Rhett P. Ketterling & Shaji K. Kumar. (2022) A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal 12:1.
Crossref
Crossref
Benjamin A. Derman, Satyajit Kosuri & Andrzej Jakubowiak. (2022) Knowing the unknowns in high risk multiple myeloma. Blood Reviews 51, pages 100887.
Crossref
Crossref
Neeraj Sharma, James B. Smadbeck, Nadine Abdallah, Cinthya Zepeda-Mendoza, Moritz Binder, Kathryn E. Pearce, Yan W. Asmann, Jess F. Peterson, Rhett P. Ketterling, Patricia T. Greipp, P. Leif Bergsagel, S. Vincent Rajkumar, Shaji K. Kumar & Linda B. Baughn. (2021)
The Prognostic Role of
MYC
Structural Variants Identified by NGS and FISH in Multiple Myeloma
. Clinical Cancer Research 27:19, pages 5430-5439.
Crossref
Crossref
Joan Enric Ramis-Zaldivar, Blanca Gonzalez-Farre, Alina Nicolae, Svetlana Pack, Guillem Clot, Ferran Nadeu, Anja Mottok, Heike Horn, Joo Y Song, Kai Fu, George Wright, Randy D. Gascoyne, Wing C. Chan, David W. Scott, Andrew L. Feldman, Alexandra Valera, Anna Enjuanes, Rita M. Braziel, Erlend B. Smeland, Louis M. Staudt, Andreas Rosenwald, Lisa M. Rimsza, German Ott, Elaine S Jaffe, Itziar Salaverria & Elias Campo. (2021) MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica 106:10, pages 2682-2693.
Crossref
Crossref
Ignacio J. Cardona-Benavides, Cristina de Ramón & Norma C. Gutiérrez. (2021) Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 10:2, pages 336.
Crossref
Crossref
Masato Yasumi, Takaya Endo, Hiroshi Sata & Takahiro Karasuno. (2020) Double-Hit Primary Plasma Cell Leukemia with IGH/MYC and IGH/CCND1 Translocations. Case Reports in Hematology 2020, pages 1-5.
Crossref
Crossref
Nadine Abdallah, Linda B. Baughn, S. Vincent Rajkumar, Prashant Kapoor, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Ronald S. Go, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Yi Lin, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Mustaqeem Siddiqui, John Lust, Robert A. Kyle, Rhett Ketterling, Leif Bergsagel, Patricia Greipp & Shaji K. Kumar. (2020) Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research 26:24, pages 6581-6588.
Crossref
Crossref
Jianxuan Zou, Richard J. Jones, Hua Wang, Isere Kuiatse, Fazal Shirazi, Elisabet E. Manasanch, Hans C. Lee, Robert Sullivan, Leah Fung, Normand Richard, Paul Erdman, Eduardo Torres, David Hecht, Imelda Lam, Brooke McElwee, Aparajita H. Chourasia, Kyle W. H. Chan, Frank Mercurio, David I. Stirling & Robert Z. Orlowski. (2020) The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. Journal of Molecular Medicine 98:8, pages 1161-1173.
Crossref
Crossref
Alessandra Di Bacco, Nizar J. Bahlis, Nikhil C. Munshi, Hervé Avet‐Loiseau, Tamás Masszi, Luísa Viterbo, Ludek Pour, Peter Ganly, Michele Cavo, Christian Langer, Shaji K. Kumar, S. Vincent Rajkumar, Jonathan J. Keats, Deborah Berg, Jianchang Lin, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Dixie‐Lee Esseltine, Katarina Luptakova, Helgi Velde, Paul G. Richardson & Philippe Moreau. (2020) c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. European Journal of Haematology 105:1, pages 35-46.
Crossref
Crossref
Katsuya Yamamoto, Kimikazu Yakushijin, Mitsuhiro Ito, Hideaki Goto, Ako Higashime, Kazuyoshi Kajimoto, Yoshitake Hayashi, Hiroshi Matsuoka & Hironobu Minami. (2020) MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes. Cancer Genetics 242, pages 35-40.
Crossref
Crossref
Yusuke Furukawa & Jiro Kikuchi. (2020) Molecular basis of clonal evolution in multiple myeloma. International Journal of Hematology 111:4, pages 496-511.
Crossref
Crossref
James Smadbeck, Jess F. Peterson, Kathryn E. Pearce, Beth A. Pitel, Andrea Lebron Figueroa, Michael Timm, Dragan Jevremovic, Min Shi, A. Keith Stewart, Esteban Braggio, Daniel L. Riggs, P. Leif Bergsagel, George Vasmatzis, Hutton M. Kearney, Nicole L. Hoppman, Rhett P. Ketterling, Shaji Kumar, S. Vincent Rajkumar, Patricia T. Greipp & Linda B. Baughn. (2019) Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer Journal 9:12.
Crossref
Crossref
Rolando García, Weina Chen & Prasad Koduru. (2018) Clinical impact of MYC abnormalities in plasma cell myeloma. Cancer Genetics 228-229, pages 115-126.
Crossref
Crossref
Hanne E. H. Møller, Birgitte S. Preiss, Per Pedersen, Brian Østergaard, Mikael Frederiksen, Niels Abildgaard & Michael B. Møller. (2018) Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. European Journal of Haematology 101:5, pages 585-590.
Crossref
Crossref
Xiaohui Zhang, Hans C. Lee, Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin, Isere Kuiatse, Hua Wang, Richard J. Jones, Zuzana Berkova, Ram Kumar Singh, Jing Lu, Yimin Qian, Kanak Raina, Kevin G. Coleman, Craig M. Crews, Bingzong Li, Huihan Wang, Yared Hailemichael, Sheeba K. Thomas, Zhiqiang Wang, R. Eric Davis & Robert Z. Orlowski. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:10, pages 2224-2239.
Crossref
Crossref
Jean Fan, Hae-Ock Lee, Soohyun Lee, Da-eun Ryu, Semin Lee, Catherine Xue, Seok Jin Kim, Kihyun Kim, Nikolaos Barkas, Peter J. Park, Woong-Yang Park & Peter V. Kharchenko. (2018) Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Research 28:8, pages 1217-1227.
Crossref
Crossref
Elina Alaterre, Sebastien Raimbault, Hartmut Goldschmidt, Salahedine Bouhya, Guilhem Requirand, Nicolas Robert, Stéphanie Boireau, Anja Seckinger, Dirk Hose, Bernard Klein & Jérôme Moreaux. (2017)
CD24
,
CD27
,
CD36
and
CD302
gene expression for outcome prediction in patients with multiple myeloma
. Oncotarget 8:58, pages 98931-98944.
Crossref
Crossref
Charlotte Pawlyn & Gareth J. Morgan. (2017) Evolutionary biology of high-risk multiple myeloma. Nature Reviews Cancer 17:9, pages 543-556.
Crossref
Crossref
Hans C. Lee, Hua Wang, Veerabhadran Baladandayuthapani, Heather Lin, Jin He, Richard J. Jones, Isere Kuiatse, Dongmin Gu, Zhiqiang Wang, Wencai Ma, John Lim, Sean O'Brien, Jonathan Keats, Jing Yang, Richard E. Davis & Robert Z. Orlowski. (2017)
RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target
MYC
in Multiple Myeloma
. British Journal of Haematology 177:1, pages 80-94.
Crossref
Crossref
Amrita Krishnan. (2016) How to Think About Risk in Myeloma. Clinical Lymphoma Myeloma and Leukemia 16, pages S135-S138.
Crossref
Crossref
Miroslava Mlynarcikova, Jana Balcarkova, Pavla Mickova, Vlastimil Scudla, Tomas Pika, Jaroslav Bacovsky, Jiri Minarik, Eva Janousova & Marie Jarosova. (2016) Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. Clinical Lymphoma Myeloma and Leukemia 16:6, pages 358-365.
Crossref
Crossref
Karen S. Bishop, Dug Yeo Han, Nishi Karunasinghe, Megan Goudie, Jonathan G. Masters & Lynnette R. Ferguson. (2016) An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer. PeerJ 4, pages e1731.
Crossref
Crossref
Sai HuangHua YangYan LiCong FengLi GaoGuo-feng ChenHong-hao GaoZhi Huang, Yong-hui LiLi Yu. (2016) Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia. Medical Science Monitor 22, pages 3009-3017.
Crossref
Crossref
A M Rajan & S V Rajkumar. (2015) Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer Journal 5:10, pages e365-e365.
Crossref
Crossref
Huabo Wang, Peter Teriete, Angela Hu, Dhanya Raveendra-Panickar, Kelsey Pendelton, John S. Lazo, Julie Eiseman, Toril Holien, Kristine Misund, Ganna Oliynyk, Marie Arsenian-Henriksson, Nicholas D. P. Cosford, Anders Sundan & Edward V. Prochownik. (2015) Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. Oncotarget 6:32, pages 32380-32395.
Crossref
Crossref